يعرض 901 - 920 نتائج من 9,652 نتيجة بحث عن 'significantly ((((((less decrease) OR (larger decrease))) OR (mean decrease))) OR (we decrease))', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 901

    XRD analysis [17]. حسب Saleh Ahmed Aldahash (16441937)

    منشور في 2025
    الموضوعات:
  2. 902
  3. 903

    Contains R code utilized in the analyses. حسب Arttu Autio-Kimura (20454681)

    منشور في 2024
    "…Spearman correlation analysis between the individuals’ calendar ages and cell type proportions revealed a statistically significant decrease in the proportion of neurons with increasing age. …"
  4. 904
  5. 905
  6. 906
  7. 907
  8. 908
  9. 909
  10. 910
  11. 911

    Flow chart of experimental protocol. حسب Eun-Seon Yang (19751340)

    منشور في 2024
    "…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …"
  12. 912

    A representative ultrasound axis image. حسب Eun-Seon Yang (19751340)

    منشور في 2024
    "…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …"
  13. 913
  14. 914
  15. 915
  16. 916
  17. 917
  18. 918
  19. 919

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  20. 920

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"